These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 17085206)

  • 1. Re: The Prostate Cancer Prevention Trial: design, biases and interpretation of study results. P. J. Goodman, I. M. Thompson, Jr., C. M. Tangen, J. J. Crowley, L. G. Ford and C. A. Coltman, Jr., J Urol, 175: 2234-2242, 2006.
    Walsh PC
    J Urol; 2006 Dec; 176(6 Pt 1):2744; author reply 2744. PubMed ID: 17085206
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy I. M. Thompson, C. M. Tangen, D. P. Ankerst, C. Chi, M. S. Lucia, P. Goodman, H. Parnes and C. A. Coltman, Jr. J Urol 2008; 180: 544-547.
    Atmaca AF; Balbay MD
    J Urol; 2009 May; 181(5):2387-8. PubMed ID: 19303084
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: Thompson IM, Klein EA, Lippman SM, Coltman CA, Djavan B. Prevention of prostate cancer with finasteride: US/European perspective. Eur Urol 2003;44:650-5.
    Pitts WR
    Eur Urol; 2004 Jul; 46(1):133-4. PubMed ID: 15183559
    [No Abstract]   [Full Text] [Related]  

  • 4. Prevention of prostate cancer with finasteride.
    Burke HB
    N Engl J Med; 2003 Oct; 349(16):1569-72; author reply 1569-72. PubMed ID: 14562806
    [No Abstract]   [Full Text] [Related]  

  • 5. Prostate cancer prevention and finasteride.
    D'Amico AV; Barry MJ
    J Urol; 2006 Nov; 176(5):2010-2; discussion 2012-3. PubMed ID: 17070238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Re: Chemoprevention of prostate cancer. I. M. Thompson, C. M. Tangen, P. J. Goodman, M. S. Lucia and E. A. Klein. J Urol 2009; 182: 499-508.
    Schellhammer PF
    J Urol; 2010 Mar; 183(3):1258-9; author reply 1259. PubMed ID: 20097380
    [No Abstract]   [Full Text] [Related]  

  • 7. Preventing prostate cancer. Finasteride shrinks enlarged prostates and may prevent some cases of prostate cancer. But it's no panacea.
    Beer TM
    Health News; 2003 Aug; 9(8):1-2. PubMed ID: 12971313
    [No Abstract]   [Full Text] [Related]  

  • 8. The prostate cancer prevention trial: design, biases and interpretation of study results.
    Goodman PJ; Thompson IM; Tangen CM; Crowley JJ; Ford LG; Coltman CA
    J Urol; 2006 Jun; 175(6):2234-42. PubMed ID: 16697846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-grade prostate cancer in the Prostate Cancer Prevention Trial: fact or artifact?
    Andriole GL; Humphrey PA; Serfling RJ; Grubb RL
    J Natl Cancer Inst; 2007 Sep; 99(18):1355-6. PubMed ID: 17848666
    [No Abstract]   [Full Text] [Related]  

  • 10. New finasteride trial results aim to curb controversy.
    Bankhead C
    J Natl Cancer Inst; 2006 Aug; 98(16):1104-5. PubMed ID: 16912260
    [No Abstract]   [Full Text] [Related]  

  • 11. The evolution of the PCPT from clinical to molecular analyses.
    Hoque A
    Nat Clin Pract Oncol; 2006 Nov; 3(11):581. PubMed ID: 17080169
    [No Abstract]   [Full Text] [Related]  

  • 12. Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial.
    Cohen YC; Liu KS; Heyden NL; Carides AD; Anderson KM; Daifotis AG; Gann PH
    J Natl Cancer Inst; 2007 Sep; 99(18):1366-74. PubMed ID: 17848668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial.
    Etzioni RD; Howlader N; Shaw PA; Ankerst DP; Penson DF; Goodman PJ; Thompson IM
    J Urol; 2005 Sep; 174(3):877-81. PubMed ID: 16093979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of prostate cancer with finasteride.
    Ross RK; Skinner E; Cote RJ
    N Engl J Med; 2003 Oct; 349(16):1569-72; author reply 1569-72. PubMed ID: 14562807
    [No Abstract]   [Full Text] [Related]  

  • 15. High-grade prostate cancer and finasteride.
    Lebdai S; Bigot P; Azzouzi AR
    BJU Int; 2010 Feb; 105(4):456-9. PubMed ID: 19930174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Prostate Cancer Prevention Trial: current status.
    Higgins B; Thompson IM
    J Urol; 2004 Feb; 171(2 Pt 2):S15-7; discussion S8. PubMed ID: 14713747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Re: Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. S. J. Freedland, E. A. Platz, J. C. Presti Jr., W. J. Aronson, C. L. Amling, C. J. Kane and M. K. Terris. J Urol, 175: 500-504, 2006.
    Stamatiou K; Alevizos A; Mariolis A; Sofras F
    J Urol; 2006 Sep; 176(3):1251-2; author reply 1252. PubMed ID: 16890735
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial.
    Walsh PC
    J Urol; 1999 Jan; 161(1):350-1. PubMed ID: 10037436
    [No Abstract]   [Full Text] [Related]  

  • 19. Re: Long-term effects of finasteride on prostate specific antigen levels: results from the Prostate Cancer Prevention Trial.
    Walsh PC
    J Urol; 2006 Jul; 176(1):409-10; author reply 410. PubMed ID: 16753454
    [No Abstract]   [Full Text] [Related]  

  • 20. The clinical implications of the prostate cancer prevention trial.
    Marberger M; Adolfsson J; Borkowski A; Fitzpatrick J; Kirk D; Prezioso D; Rabaça C; Solsona E; Teillac P
    BJU Int; 2003 Nov; 92(7):667-71. PubMed ID: 14616442
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.